Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.

Journal: Lancet (London, England)
Published Date:

Abstract

BACKGROUND: Improved markers of prognosis are needed to stratify patients with early-stage colorectal cancer to refine selection of adjuvant therapy. The aim of the present study was to develop a biomarker of patient outcome after primary colorectal cancer resection by directly analysing scanned conventional haematoxylin and eosin stained sections using deep learning.

Authors

  • Ole-Johan Skrede
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
  • Sepp De Raedt
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
  • Andreas Kleppe
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
  • Tarjei S Hveem
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • Knut Liestøl
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
  • John Maddison
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • Hanne A Askautrud
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • Manohar Pradhan
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • John Arne Nesheim
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • Fritz Albregtsen
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
  • Inger Nina Farstad
    Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Enric Domingo
    Department of Oncology, University of Oxford, Oxford, UK.
  • David N Church
    Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK; National Institute of Health Research Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Arild Nesbakken
    Department of Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; KG Jebsen Colorectal Cancer Research Centre, Oslo, Norway.
  • Neil A Shepherd
    Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, UK.
  • Ian Tomlinson
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
  • Rachel Kerr
    Department of Oncology, University of Oxford, Oxford, UK.
  • Marco Novelli
    Dept of Pathology, University College London Hospital (UCLH), London, United Kingdom.
  • David J Kerr
    Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.
  • Håvard E Danielsen
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway; Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK. Electronic address: hdaniels@labmed.uio.no.